https://www.selleckchem.com/pe....ptide/pki-14-22-amid
The primary outcome for assessing preliminary effectiveness is a mean score across five key symptoms that are amenable to change (ie, breathlessness, pain, anxiety, constipation, fatigue), measured at baseline and 8 weeks post-baseline. The process evaluation will be conducted in the intervention group only, with measurements at 8-11 weeks post-baseline to evaluate implementation, mechanisms of change and contextual factors. The study has been approved by the ethics committee of University Hospital Ghent. Results wi
Like
Comment
Share
